Clinical Research Details

Clinical Research

ALK3831-A307: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness

Study Description

The purpose of this study is to compare weight gain in patients taking ALKS 3831 versus patients taking only olanzapine.

After a screening period of up to 4 weeks, if you are enrolled into the study, you will visit the clinic twice in the first 2 weeks, then every other week for a further 14 weeks. If you agree to participate, you must be willing and able to visit the clinic for the entire study. You may start the study as an inpatient if the study doctor thinks you will likely be able to change to outpatient treatment within 2 weeks after starting the study drug.

Open Enrollment

Contact Name: Steven Cuffe
Contact Phone: (904) 244-3990
Contact Email:


Principal Investigator
Steven P. Cuffe, M.D., FACPsych

Sub Investigator
Phyliss N. Taylor, M.D.